TAXIS Pharmaceuticals

Taxis Pharmaceuticals

Pharmaceuticals, 9 Deerpark Dr Ste J15, Monmouth Junction, New Jersey, 08852, United States, 1-10 Employees

taxispharma.com

  • LinkedIn

phone no Phone Number: 73********

Who is TAXIS PHARMACEUTICALS

Founded in March, 2009, TAXIS Pharmaceuticals is focused on the discovery and development of pharmaceuticals targeting multidrug-resistant bacterial pathogens that constitute a worldwide ...

Read More

map
  • 9 Deerpark Dr Ste J15, Monmouth Junction, New Jersey, 08852, United States Headquarters: 9 Deerpark Dr Ste J15, Monmouth Junction, New Jersey, 08852, United States
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: $1 Million to $5 Million

industries-icon Industry: Pharmaceuticals

SIC SIC Code: 2834

checked-icon Does something look wrong? Fix it. | View contact records from TAXIS PHARMACEUTICALS

TAXIS Pharmaceuticals Org Chart and Mapping

Employees

Similar Companies to TAXIS Pharmaceuticals

Sciecure Pharma

  • 11-50 11-50
  • 5 Million to 10 Million $ 5 Million to 10 Million
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding TAXIS Pharmaceuticals

Answer: TAXIS Pharmaceuticals's headquarters are located at 9 Deerpark Dr Ste J15, Monmouth Junction, New Jersey, 08852, United States

Answer: TAXIS Pharmaceuticals's phone number is 73********

Answer: TAXIS Pharmaceuticals's official website is https://taxispharma.com

Answer: TAXIS Pharmaceuticals's revenue is $1 Million to $5 Million

Answer: TAXIS Pharmaceuticals's SIC: 2834

Answer: TAXIS Pharmaceuticals has 1-10 employees

Answer: TAXIS Pharmaceuticals is in Pharmaceuticals

Answer: TAXIS Pharmaceuticals top competitors include: Sciecure Pharma

Answer: TAXIS Pharmaceuticals contact info: Phone number: 73******** Website: https://taxispharma.com

Answer: Founded in March, 2009, TAXIS Pharmaceuticals is focused on the discovery and development of pharmaceuticals targeting multidrug-resistant bacterial pathogens that constitute a worldwide therapeutic category estimated to exceed $30B in annual sales revenues. The initial series of proprietary lead candidates, referred to as the azachryseniums (AZCs), display in vitro activity that is superior to current standards of care for a broad range of Gram-positive bacterial pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE).

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access